Purpose: To investigate the relationship of pembrolizumab pharmacokinetics (PK) and
overall survival (OS) in patients with advanced melanoma and non–small cell lung cancer …

Pembrolizumab is a monoclonal antibody that targets the programmed death-1 receptor to
induce immune-mediated clearance (CL) of tumor cells. Originally approved by the US Food …

Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on
body weight because of perceived contribution of body size in pharmacokinetic variability …

Introduction: Advanced melanoma is a devastating disease that has propelled research in
therapeutics beyond chemotherapy and radiotherapy. Being highly immunogenic …

Pembrolizumab, a potent antibody against programmed death 1 (PD‐1) receptor, has shown
robust antitumor activity and manageable safety in patients with advanced solid tumors. Its …

Background In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable
antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought …

Importance The programmed death 1 (PD-1) pathway limits immune responses to
melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody …

Background Pembrolizumab is approved for multiple cancer types at 200 mg and 2 mg/kg
dose every 3 weeks (Q3W). We used a model-based approach to compare the exposure of …

Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as
these may influence individual treatment selection or sequence. We aimed to identify …

While many patients are treated beyond progression (TBP), the magnitude and duration of
clinical benefit in these patients have not been fully quantified. Data from 799 patients with …